| Name | Relationship | Address | Signature | Signature date | CIK |
|---|---|---|---|---|---|
| Luly Jay R. | President and CEO, Director | C/O ENANTA PHARMACEUTICALS, INC., 4 KINGSBURY AVENUE, WATERTOWN | /s/ Matthew Kowalsky as attorney-in-fact | 13 Feb 2026 | 0001571211 |
| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | ENTA | Common Stock | Award | $0 | +4,800 | +0.56% | $0.000000 | 862,826 | 12 Feb 2026 | Direct | F1 |
| transaction | ENTA | Common Stock | Award | $0 | +15,200 | +1.8% | $0.000000 | 878,026 | 12 Feb 2026 | Direct | F2 |
| transaction | ENTA | Common Stock | Tax liability | $87,709 | -6,155 | -0.7% | $14.25 | 871,871 | 12 Feb 2026 | Direct | F3 |
| Id | Content |
|---|---|
| F1 | Represents shares of Enanta common stock issued under performance share units ("PSUs") that vested as a result of performance against two-year research and development milestones in the calendar 2024-2025 period as determined by the Compensation Committee of Enanta's Board of Directors, and then settled with the issuance of the shares of Enanta common stock on February 12, 2026. |
| F2 | Represents shares of Enanta common stock issued under a relative total stockholder return unit ("rTSRU") award that was subject to performance-vesting restrictions based on the relative total stockholder return of Enanta's common stock in relation to the total stockholder return of the component companies in the Nasdaq Biotech Index over the same 60-day calendar periods two years apart. The performance level was determined by the Compensation Committee of Enanta's Board of Directors and the rTSRU settled with the issuance of the shares of Enanta common stock on February 12, 2026. |
| F3 | Represents the number of shares of common stock automatically forfeited by the reporting person to cover withholding taxes due as a result of settlement of the PSU and rTSRU awards. |